Head-to-head · WeighScore
Intimate Rose vs Omada Health
The verdict
Intimate Rose takes it — 69.3/100 to 55.6/100.
Intimate Rose grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Intimate Rose is an established US women's and pelvic-health brand that has added an online weight-management program offering compounded GLP-1 medication.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Intimate Rose | Omada Health |
|---|---|---|
| WeighScore | 69.3/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #126 | #435 |
| Semaglutide | $169/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $169/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #126 · C
Strengths
- Transparent pricing from 169 dollars per month shown upfront, not gated behind intake
- Medication and free delivery included, HSA and FSA eligible, no contract
- Backed by an established women's-health brand using the OpenLoop provider network
Where it loses points
- State availability not published
- Oral compounded GLP-1 only; no injectable option shown
- No specific compounding pharmacy named (network fulfillment via OpenLoop)
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.